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Craniocerebral aspergillosis in immunocompetent hosts: 
Surgical perspective
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Rashid Jooma*, Saleha Anwar**
Division of Neurosurgery, The Aga Khan University, *Department of Neurosurgery, Jinnah Postgraduate Medical Centre, **Department of 
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Surgical treatment of fungal infections of the central 
nervous system (CNS) has always been a challenge to 
the neurosurgeon. The CNS may be involved primarily, 
as primary intracranial infection or secondarily through 
hematogenous spread of the disease from elsewhere. 
Fungal infection can also spread directly from adjacent 
structures, notably sinonasal disease. Fungal infection 
of the CNS is extremely dangerous, affecting mainly the 
immunocompromised hosts with a reported mortality of 
almost 100% in earlier literature. Fortunately, the disease 
is relatively uncommon, accounting for less than five 
per cent of all CNS infections and was even referred to 
as almost always a clinical surprise in a recent review 
by Nadkarni and Goel.[1] However, recently we have 
noticed a rise in the reporting of fungal infections of 
the CNS.[2-8] The reason for this can be the increasing 
number of immunocompromised patients due to the 
growing epidemic of acquired immunodeficiency 
syndrome (AIDS), chronic granulomatous diseases, 
autoimmune diseases or due to the increasing population 
of patients having had solid organ transplants and 
on immunosuppressants. The reason can also be 
the widespread availability of neuroimaging i.e. 
computerized tomography (CT) and MRI scanning 
which has lead to earlier diagnosis and thus earlier 
referrals to neurosurgical centers. 
Of late a newer class of patients have been recognized, 
those who are apparently immunocompetent, harboring 
CNS fungal infections. These cases present an 
interesting diagnostic dilemma for the neurosurgeons 
and neuroradiologists, as neither the clinical nor the 
imaging features of CNS fungal infections are truly 
diagnostic of the disease and with the patient being 
immunocompetent, the possibility of fungal infection 
is considered low on the list of differentials.[9] 
Pathophysiology
Aspergillus fumigatus is the most commonly identified 
human pathogen, especially in immunocompromised 
hosts. Since Aspergillus spores are commensals in 
the respiratory tract and external auditory canal, it 
is understandable why maxillary sinusitis and lungs 
are the most common sites of primary aspergillus 
infection. Primary aspergillosis of the paranasal sinus 
has been classically described to be of two kinds; either 
noninvasive (also called allergic Aspergillus sinusitis) or 
invasive. Infection may reach the CNS either through 
direct spread or hematogenous spread. Erosion of bone is 
not always necessary for direct intracranial extension as 
the fungus has the propensity to spread along vessels that 
serve as direct channels for the seeding of aspergilli. 
Craniocerebral aspergillosis is a rare but dangerous variety 
of central nervous system infections. Surgery is being widely 
recognized as the cornerstone of management. Due to the 
rarity of the disease, difÞ culty and delay in diagnosis and 
poor outcome, there is very little in the literature regarding 
the various surgical strategies that may be adopted in these 
patients. Early aggressive surgery followed by chemotherapy 
offers the best chances. Surgical planning would depend upon 
the type and location of the disease process as well as the 
condition of the patient. Perioperative care holds immense 
importance and knowledge of possible complications is 
essential. Aspergillosis of the central nervous system is difÞ cult 
to diagnose and equally difÞ cult to treat. Surgery remains the 
cornerstone of management followed by systemic antifungal 
medications. Results are better in immunocompetent patients 
as compared to those who are immunocompromised.
Key words: Aspergillosis, fungal infections, immunocompetent 
hosts
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Single or multiple abscesses with marked vascular 
invasion with or without thrombosis is the hallmark 
of cerebral aspergillosis on pathologic examination. 
Aspergillus has a tendency to invade vessels producing 
a sort of necrotizing angiitis leading to secondary 
thrombosis with or without hemorrhage. Fungal hyphae 
are found in large, intermediate and small blood vessels 
with invasion through vascular walls into adjacent 
tissue. The evolving hemorrhagic infarcts later convert 
into septic infarcts with associated abscesses and 
cerebritis. The mechanism of damage at the cellular 
level in cerebral Aspergillus lesions has been recently 
shown to be due to secretion of various necrotizing 
factors with toxic and lytic activity toward neurons and 
glial cells.[10] Although the mechanism of invasiveness 
in immunologically competent hosts remains unclear, it 
is possibly caused by qualitative cellular or sub-cellular 
immunodeficiency that is either unrecognized or poorly 
characterized. Nevertheless, formation of granulomas 
and the presence of epithelioid and multinucleate giant 
cells in these patients indicate at least some integrity 
of immune response. Purulent lesions may be chronic 
and have a tendency towards fibrosis and granuloma 
formation. In purulent lesions, pus is seen in the 
centre of the abscesses with abundant polymorphs at 
the periphery. Granulomas consist of lymphocytes, 
plasma cells and fungal hyphae.[11] In summary, brain 
abscess, epidural abscess, vasculitis, stroke-like illness, 
granulomatous mass and meningitis are the various 
types of CNS aspergillosis.[12]
Presentation 
Classically, craniocerebral aspergillosis should be 
considered in any patient known or suspected to be 
immunocompromised, presenting with signs, symptoms 
and radiological features of space-occupying lesion 
with or without a preceding history of nasal blockade/ 
discharge. Multiple studies have described a variety 
of presenting symptoms such as nasal stuffiness, 
headache, peri-orbital pain, vomiting, convulsions, 
hemiparesis, cranial nerve deficits (diplopia/anosmia), 
proptosis, sensory impairment, dysarthria, lethargy, 
impaired consciousness and seizures with or without 
fever and rarely, ear discharge.[3,13,14] In patients with 
paranasal sinus disease orbital extension with proptosis, 
ophthalmoplegia, visual deterioration (which may 
lead to total monocular blindness) and chemosis may 
occur. Another feature usually associated with these 
patients is hypertelorism. Features typical of meningitis 
and subarachnoid hemorrhage resulting from mycotic 
aneurysms may also manifest.[11,15] The disease is usually 
slowly progressive and symptoms may persist for 
months. Alternatively, patients may also present acutely 
with cerebral infarctions or hemorrhage, a manifestation 
of vascular invasion of the fungus.[16] Aspergillosis has 
been shown to have a tendency for invasion of the 
walls of both small and large blood vessels, which may 
lead to either thrombosis and subsequent infarction or 
equally dangerous hemorrhage. The organism can also 
spread beyond the vessel walls and form abscesses in 
the altered brain tissue.
Radiological Diagnosis 
The findings in the conventional CT scan and magnetic 
resonance (MR) imaging are frequently minimal or absent 
in the hyperacute stage of CNS aspergillosis.[17,18] On CT 
scanning, a number of features have been reported, 
though none are specific for fungal disease. Presence 
of a hyperdense mass lesion in the sinuses along with 
bony expansion or erosion of sinus walls and/or cranial 
base is frequently observed in patients [Figures 1 and 
2] having intracranial aspergillosis of sinonasal origin 
i.e. the invasive variety of aspergillosis.[2,12] Abscesses 
demonstrate ring or homogenous enhancement along 
with mass effect. At times there may be slight or 
Shamim, et al.: Surgical management of craniocerebral aspergillosis 
Figure 1: CT scan coronal sections showing Aspergillus involvement 
of paranasal sinuses with intra-cranial extension, typical of invasive 
aspergillosis. Patient was immunocompetent
Figure 2: CT scan coronal section showing sinonasal disease eroding the 
cribiform plate and extending intracrially. Patient was immunocompetent 
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even no contrast enhancement [Figures 3-5]. Early 
hemorrhage or infarctions are other features associated 
with aspergillosis and should raise the suspicion in 
immunocompromised hosts. Overall, CT scanning 
not only helps in the diagnosis but is also helpful in 
providing a convenient way to monitor the patients 
response to antimicrobial therapy. 
On MR imaging, the classical description is that of an 
irregular space-occupying mass lesion having hypo- to 
iso-intense signals on T1-weighted images [Figure 6], 
extremely low signals on T2-weighted images with 
either bright homogenous enhancement on post-
gadolinium T1 weighted images or ring enhancement 
pattern. At times a thick irregul r wall of mass lesions 
on CT and MR imaging is apparent, which indicates a 
competent host defense mechanism that is attempting 
to isolate or encapsulate the offending organisms. The 
differential diagnosis of multiple brain lesions in an 
immunocompromised patient includes lymphoma, 
metastatic disease, septic emboli, tuberculomas and 
multiple infarcts. It may be mentioned here, that the 
diagnosis of aspergillosis in all cases is supported with 
the involvement of paranasal sinuses but as for all 
reported features, it is also not diagnostic on its own. 
Surgical Management 
There are no specific treatment guidelines for 
intracranial aspergillosis, as detailed data on patient 
survival is only available from case reports and case 
series.[19,20] Despite newer, safer and more effective 
antifungal medications, it is generally agreed that the 
cornerstone of treatment remains surgical excision. 
This is based largely on reports of personal experience; 
and more recently on the basis of a multifactorial risk 
analysis done by Schwartz et al. on the data of a study 
population comprising mainly immunocompromised 
patients on variconazole therapy, which suggested 
improved outcomes in patients who had undergone 
neurosurgical intervention.[19] Besides, there are very few 
reports of patients surviving CNS aspergillosis on medical 
treatment alone.[20,21] It cannot be overemphasized 
that surgical excision must always be followed by 
aggressive antifungal chemotherapy to achieve the best 
response.[19,22-26] It has been observed that radical surgery 
done early and as a first procedure is better than repeated 
attempts at sub-radical resection.[27] We have reported 
our own experience from two large university hospitals 
of Karachi and in our experience radical excision of 
fungal mass does not seem to be necessary.[2] Radical 
surgery involving risks of morbidity seems excessive 
for an infective process. Sub-radical excision aimed at 
establishing diagnosis and reducing disease burden, 
in process,  avoiding the risks of permanent iatrogenic 
neurological deficits, followed by systemic antifungal 
Shamim, et al.: Surgical management of craniocerebral aspergillosis 
Figures 3, 4, 5: Axial T1 weighted image showing hypo-intense right frontoparietal lesion. T2 weighted image of same showing 
hyper-intense signals with patchy iso to hypo-intensities. There is signiÞ cant edema and mass effect. On contrast administration, 
the lesion showed patchy enhancement, mainly at the center of the lesion. These Þ ndings are not typical of aspergillus disease, 
although the pathology conÞ rmed this to be aspergillosis. Patient was immunocompetent 
3 4 5
Figure 6: Axial T1 weighted image with gadolinium enhancement 
showing nasal and left orbital involvement with left proptosis. Patient 
also has a left temporal ring-enhancing abscess in the absence of bony 
erosion. The lesions turned out to be Aspergillus in etiology. Patient was 
immunocompetent 
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therapy seems to be a better course of action. However, 
whenever faced with a surgically removable lesion in a 
noneloquent area, the best plan would be to eradicate 
the lesion completely rather than sub-radical resection. 
Sub-radical resection may be reserved for lesions which 
are only partially resectable. Obviously, in a lesion 
occupying an eloquent area, where iatrogenic permanent 
neurological deficits seem inevitable even if sub-radical 
excision is attempted, a biopsy would suffice. 
A similar approach is advisable in case of cerebral 
aspergillus abscesses. These should be excised 
completely if there is no risk of further neurological 
deficits as complete excision has been shown to improve 
outcome.[28] Even lobectomy, in patients with a single 
aspergillus abscess is an acceptable surgical option when 
noneloquent areas of the brain are involved. In the series 
reported by Nadkarni and Goel, four of seven patients 
with cerebral aspergillosis who survived, complete 
surgical resection of brain abscess was accomplished.[1] 
On the other hand, when eloquent brain areas are 
found to harbor an aspergillus abscess, aspiration 
may be the only surgical option which may be done 
more precisely under neuronavigation or stereotactic 
guidance, especially if the abscesses are deep-seated. It 
should be borne in mind that abscess fluid may not be 
diagnostic in all cases as fungal hyphae are abundant 
largely in the abscess rim rather than the necrotic center. 
For best diagnostic yields, multiple specimens from both 
the rim and center should be sought. This procedure 
may also be carried out in awake patients under local 
anesthesia using burr hole or mini craniotomy. Necrotic 
brain tissue and granulomas are likewise subjected to 
radical debridement which would theoretically enhance 
antibiotic penetration and reduce fungal load by removal 
of debris. Extradural disease is less complicated to 
deal with and should be treated according to basic 
neurosurgical principles established for other forms of 
exradural abscesses, followed of course by antifungal 
therapy. 
Whenever the nasal passages are suspected to be 
involved, we strongly recommend thorough clearance 
of nasal passages, thereby depriving the fungus of a 
potential microaerophilic environment otherwise suitable 
for its proliferation. For this purpose, we have benefi ted 
greatly from endoscopic sinus surgery, which requires 
the help of ENT surgeons. The procedure may need to be 
repeated more than once for adequate clearance of nasal 
passages and sinuses. When the globe is also involved 
the patient mostly does not have vision in that eye and 
enucleation should be considered and discussed with 
the patient. This becomes even more diffi cult when the 
globe is clearly affected by the fungus but the vision is 
intact. In such cases, preservation of the eye with serial 
monitoring with MRI and objective ophthalmological 
examinations such as perimetry and visual evoked 
potentials may be considered. The management therefore 
requires multidisciplinary team approach involving 
the neurosurgeon, ENT surgeon, ophthalmologist, 
maxillofacial surgeon, neuroradiologist, intensivist, 
infectious disease expert and clinical pharmacist. 
Perioperative management of these patients requires 
special mentioning. It is a critical time period which 
starts from the time of incision and lasts almost a week or 
even longer. It is the most difficult part of management 
and from our experience we have learned that it requires 
more vigilance and aggression than perhaps the surgery 
itself. The Aspergillus shows a peculiar response to 
surgery, not reported for any other disease process. 
The disease process which may have been present for 
some time, flares up postoperatively assuming a rapidly 
fulminant course if not dealt with immediately and 
aggressively. The hallmark of this unusual response is 
high-grade fever, tachycardia and rapidly increasing 
diffuse cerebral edema causing a potentially fatal rise in 
intracranial pressure refractory to medical management, 
a series of events that we refer to as the Forest Fire 
Phenomenon. The reason for this unique stormy 
postoperative course is incompletely understood but may 
be explained on the basis of either the patient becoming 
immunocompromised secondary to surgery or due to 
the manipulation of organism catalyzing the stimulation 
of previously quiescent fungi. This eventually leads 
to widespread catastrophic angio-invasion causing 
massive cerebral edema as well as possibly massive 
release of cytokines. Another possibility is that of acute 
Aspergillus meningo-encephalitis which may also lead 
to diffuse cerebral edema. The organisms response to 
surgery is sometimes apparent even intraoperatively 
as the patients body temperature begins to rise, at 
times beyond 40 degrees and the brain starts to swell 
up rapidly. We recommend that the surgery for fungal 
infections be of shortest possible duration, yet as 
aggressive as possible. At the slightest intraoperative 
impression of increasing brain swelling, serious thought 
should be given to keeping the bone flap off and doing 
duroplasty, thus allowing the brain to further swell up 
without the risk of herniation. Indeed, we have had to 
take the patient back to the operating room at times twice 
within the first 48h to deal with the increasing brain 
swelling which is refractory to medical management. 
As a result, we now routinely monitor intracranial 
pressure in these patients postoperatively with an 
intra-ventricular catheter, keep them in intensive care 
units and manage them with high doses of Mannitol. 
The role of steroids is questionable, as hypothetically it 
would further compromise the patients immune status 
but on the other hand, it may help control the edema 
on virtue of its effect on the vasogenic component of 
cerebral edema. There is no evidence which supports 
its use or avoidance and the decision would rest with 
the neurosurgeons comfort level. The patient is kept 
intubated and intermittently sedated using Propofol 
Shamim, et al.: Surgical management of craniocerebral aspergillosis 
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which also helps in decreasing intracranial pressure. 
Continuous sedation is avoided to allow observation of 
progressive neurological deficits. Repeat neuro-imaging 
studies at appropriate intervals may be used to monitor 
the intracranial complications in the postoperative 
phase. This helps in comparing the extent of cerebral 
edema and also in ruling out acute hemorrhage 
and hydrocephalus, two established postoperative 
complications as we shall discuss later. At the slightest 
hint of increasing cerebral edema and impending 
herniation, a decompressive craniotomy is undertaken. 
Decompression may just involve removing the bone flap 
with or without duroplasty, frontal lobectomy, temporal 
lobectomy with or without uncusectomy or all of the 
mentioned procedures depending upon the degree of 
swelling. The craniotomy may need to be extended 
under such circumstances to increase the size of bone 
flap which is to be removed. The bone flap may be 
saved in the patients anterior abdominal wall which 
has the advantage of showing early signs of infection 
and also convenience if the patient needs to be shifted to 
another hospital. We, however, preserve our bone flaps 
sterilized in subfreezing temperatures in a dedicated 
bone bank. We do not see any point in discarding the 
bone flap and later using acrylic for cranioplasty in such 
patients, however individual practices may vary. If the 
bone flap is in close proximity of fungal mass, alternate 
closure methods may be considered. Autoc aving the 
bone before putting it back is also an option under such 
circumstances.
In the postoperative period, special attention should 
be given to the patients metabolic profile, as the patient 
is under the influence of a number of factors which may 
lead to metabolic derangements and may jeopardize 
the entire management. These factors include fungal 
sepsis secondary to manipulation of the fungal mass, 
high-grade fever and possible risk of acute renal failure 
due to combined insults from sepsis, mannitol and most 
importantly the antifungal medications. Electrolyte 
imbalance may occur acutely and all electrolytes 
need to be repeated and corrected every two to four 
hours. Patient is kept on regular high-dose analgesics 
and anti-pyretic to avoid any increase in intra-cranial 
pressure (ICP) secondary to pain or fever. We tend 
to avoid non-steroidal anti-inflammatory drugs for 
the possible nephrotoxicity and platelet dysfunction 
despite their superiority in controlling both fever and 
pain. Continuous invasive blood pressure monitoring 
using an arterial line is mandatory. The mean arterial 
pressure (MAP) is kept at around 100-110 as too low may 
induce infarctions in the swollen brain and too high may 
further worsen the ICP. Any rapid rise in MAP and ICP 
should suggest ongoing complications. Fluid balance 
is also critical as too much fluid may increase cerebral 
edema and too little may worsen renal failure. A central 
venous line is therefore essential and a central venous 
pressure (CVP) of 8-10 is desirable, keeping the patient 
euvolemic. Persistently low CVP refractory to fluid 
challenges suggests systemic vasodilatation secondary 
to fungal sepsis and should be dealt with systemic 
vasoconstrictors. We generally prefer nor-epinephrine 
for this which is started at the lowest possible dose and 
adjusted according to the patients need. Our choice of 
fluid was isotonic saline (0.9%) as theoretically it has the 
least effect on ICP. In case of worsening ICP, hypertonic 
saline may also be considered. The urine output must 
be maintained at above 1-2 ml/kg body weight and in 
case of fall in urine output, rise in blood urea, nitrogen 
and creatinine levels, hemodyalisis may need to be 
considered as an alternate to discontinuing nephrotoxic 
antifungal medications. The multidisciplinary team 
approach is most important in this timeframe. Cardiac 
arrhythmias may be precipitated due to both sepsis 
and electrolyte imbalance and in a patient with a 
cardiac history or showing abnormal rhythm, a Swan-
Ganz catheter may be required depending upon the 
internists decision. The neurosurgery team must 
always be involved in all decisions, for at times a central 
complication may manifest as a systemic one and may 
be missed by those not trained in neuro-intensive 
care. We routinely keep our patients on anti-epileptic 
medications starting preoperatively, although there is 
no evidence to suggest any benefit of prophylactic anti-
epileptic medications. Our argument for anti-epileptic 
drugs is based on the extremely critical condition of 
these patients postoperatively and any factor which may 
increase the intracranial pressure during this time such 
as a seizure may prove detrimental. Interestingly, such 
maneuvers are not required in patients having extradural 
disease alone. It is only when the fungus involves brain 
parenchyma and during surgery the dura is opened that 
we see the Forest Fire Phenomenon.
Adjunct Medical Management
The medical management of intracranial fungal 
infections should not be considered separately 
from the surgical management. It is complementary 
to surgery and should be considered an essential 
component of the overall management. For a long 
time, the standard therapeutic regimen for cerebral 
aspergillosis following surgery remained intravenously 
administered amphotericin B combined with or 
followed by flucytosine or itraconazole.[2,23-32] Since 
the introduction of itraconazole, the first azole with 
significant activity against Aspergillus, many multicenter 
clinical trials have proven its efficacy, in combination 
or in sequential regimen.[33-38] Two newer parenteral 
antifungal medications (echinocandins) caspofungin 
and micafungin, which were initially studied for their 
effectiveness against Candidiasis are also under scrutiny. 
However, all of the aforementioned medications are 
Shamim, et al.: Surgical management of craniocerebral aspergillosis 
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used mainly as adjuncts to surgical management, as 
despite improving outcomes compared to control 
groups; these show relatively poor penetration into the 
CNS. Amphotericin B, itraconazole and caspofungin 
all show negligible levels in CSF or brain tissue.[39-41] A 
newer triazole, voriconazole is becoming increasingly 
popular and has been shown to have a CSF to plasma 
ratio of 0.22 to 1, as well as high brain tissue levels in 
autopsy studies.[19-42] In several studies and one large 
randomized trial conducted by Herbrecht et al. recently, 
voriconazole has proven to be more effective and less 
toxic than amphotericin B and has since become the 
first line of treatment of aspergillosis.[12,43-47] Recently, 
Clemons et al. supported the potential of combination 
therapy as a mechanism to improve the outcome in CNS 
aspergillosis, showing that a combination of suboptimal 
doses of liposomal amphotericin B and voriconazole 
given concurrently had a significantly better efficacy 
in comparison with either monotherapy.[48] In addition, 
liposomal amphotericin B in combination with 
caspofungin and micafungin also showed strong trends 
towards improved efficacy. 
As a protocol, we now administer preoperative oral 
itraconazole empirically in all our patients in whom 
a diagnosis of cerebral aspergillosis is suspected on 
the basis of clinical suspicion or neuroradiological 
features. This prophylactic regimen in our published 
experience leads to improved outcomes and prolonged 
survival, even though a direct causal relationship has 
not been effectively established.[2] Some authors have 
similarly proposed preoperative amphotericin B as a 
potential factor for improving prognosis.[49,50] As for all 
rare diseases, it is not possible to scientifically comment 
upon the comparative efficacy of these prophylactic 
medications based entirely on personal experiences. A 
systemic review of the literature with the sole purpose 
of establishing the role of one or the other prophylactic 
antifungal medication is needed. It may be argued 
here that although the effectiveness of any of these 
medications preoperatively is not proven scientifically, 
they have certainly not been proven to be harmful. 
Preoperative oral itraconazole as part of the protocol 
for the management of all such patients should be 
considered seriously. A few anecdotal reports have been 
published that describe treatment with intracavitary 
amphotericin B.[20,21,51,52] In our opinion, this should only 
be considered as a last resort as there is no evidence of 
the safety and efficacy of the drug when directly instilled 
into the ventricles or the abscess cavity. 
Complications and Prognosis
The unpredictable nature of the disease is apparent 
not only in its clinical presentation, radiological 
appearance, clinical course and response to treatment, 
but also when dealing with the postoperative patient. 
Besides the general complications anticipated after 
any major cranial procedure and the adverse effects 
described for the antifungal medications, some specific 
complications reported for these patients include 
massive anaphylaxis, meningitis, mycotic aneurysm 
formation, intracerebral hemorrhage, subarachnoid 
hemorrhage and hydrocephalus. Hydrocephalus is 
usually of the communicating type, although non-
communicating type may also occur. Patients need to be 
serially monitored with CT scans for this complication 
which can easily be dealt with ventriculoperitoneal 
shunt. Perhaps the two most catastrophic complications, 
both unusual in etiology are; widespread multifocal 
dissemination in the brain parenchyma/ ventricles 
and vascular infarcts involving major cerebral vessels, 
which may be remote from the site of surgery.[2,53-59] 
Such patients show a stormy postoperative course and 
may require major debulking or even decompressive 
craniotomy to prevent herniation due to rapidly 
increasing intracranial pressures. Despite these efforts, 
patients may still succumb to the disease and those who 
survive, will have crippling neurological deficits. Both 
of these complications are attributable to subclinical or 
occult angioinvasion, which is a hallmark of the disease 
as discussed in previous sections. 
Outcome of craniocerebral aspergillosis is different in 
immunosuppressed and apparently immunocompetent 
hosts.[23,29] In immunocompromised hosts mortality is 
reported to reach more than 95% and even 100% in 
patients with underlying malignancies.[60] In apparently 
immunocompetent hosts reported mortality varies from 
center to center, but ranges from 40-80%.[1,2] Patients 
harboring mainly sinonasal disease with only orbital 
and/or cranial base bony invasion/destruction, carry a 
very good prognosis (mortality < 20%).[2] Outcome in 
extradural aspergillosis is much better than in patients 
with intracerebral involvement.[2] The dismal prognosis 
should nevertheless, not discourage the care providers 
from aggressive management of these patients as success 
stories are also frequently encountered. 
Conclusion
Aspergillus infection of the CNS is an uncommon clinical 
entity, affecting mainly the immunocompromised. The 
disease presents in a number of unusual ways and 
although a multitude of clinical, biochemical and 
radiological features have been described, the diagnosis 
remains elusive. The problem is further compounded 
when the host is apparently immunocompetent, which 
lowers the clinical suspicion. Surgery followed by 
systemic antifungal medications offers the best hope for 
survival. Despite better understanding of the offending 
organism, pathophysiology, clinical course and 
development of more effective antifungal medications, 
the prognosis remains poor. High index of suspicion, 
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early diagnosis and aggressive surgical management, 
followed by medical therapy, by an interdisciplinary 
team, may help to improve outcomes. 
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